Literature DB >> 27789657

All-cause and cancer-specific mortality in GORD in a population-based cohort study (the HUNT study).

Eivind Ness-Jensen1,2,3, Eivind Gottlieb-Vedi1, Karl Wahlin1, Jesper Lagergren1,4.   

Abstract

OBJECTIVE: Gastro-oesophageal reflux is a public health concern which could have associated oesophageal complications, including adenocarcinoma, and possibly also head-and-neck and lung cancers. The aim of this study was to test the hypothesis that reflux increases all-cause and cancer-specific mortalities in an unselected cohort.
DESIGN: The Nord-Trøndelag health study (HUNT), a Norwegian population-based cohort study, was used to identify individuals with and without reflux in 1995-1997 and 2006-2008, with follow-up until 2014. All-cause mortality and cancer-specific mortality were assessed from the Norwegian Cause of Death Registry and Cancer Registry. Multivariable Cox regression was used to calculate HRs with 95% CIs for mortality with adjustments for potential confounders.
RESULTS: We included 4758 participants with severe reflux symptoms and 51 381 participants without reflux symptoms, contributing 60 323 and 747 239 person-years at risk, respectively. Severe reflux was not associated with all-cause mortality, overall cancer-specific mortality or mortality in cancer of the head-and-neck or lung. However, for men with severe reflux a sixfold increase in oesophageal adenocarcinoma-specific mortality was found (HR 6.09, 95% CI 2.33 to 15.93) and the mortality rate was 0.27 per 1000 person-years. For women, the corresponding mortality was not significantly increased (HR 3.68, 95% CI 0.88 to 15.27) and the mortality rate was 0.05 per 1000 person-years.
CONCLUSIONS: Individuals with severe reflux symptoms do not seem to have increased all-cause mortality or overall cancer-specific mortality. Although the absolute risk is small, individuals with severe reflux symptoms have a clearly increased oesophageal adenocarcinoma-specific mortality. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  ACID-RELATED DISEASES; ADENOCARCINOMA; CANCER; EPIDEMIOLOGY; GASTROESOPHAGEAL REFLUX DISEASE

Mesh:

Year:  2016        PMID: 27789657     DOI: 10.1136/gutjnl-2016-312514

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  5 in total

Review 1.  Alternatives to Traditional Per-Oral Endoscopy for Screening.

Authors:  Judith Offman; Rebecca C Fitzgerald
Journal:  Gastrointest Endosc Clin N Am       Date:  2017-04-04

2.  Life Expectancy in Survivors of Esophageal Cancer Compared with the Background Population.

Authors:  Ellinor Lundberg; Pernilla Lagergren; Fredrik Mattsson; Jesper Lagergren
Journal:  Ann Surg Oncol       Date:  2022-02-21       Impact factor: 5.344

3.  The Association Between Gastroesophageal Reflux Disease and Non-Small Cell Lung Cancer: A Retrospective Case-Control Study.

Authors:  Shivantha Amarnath; Adam Starr; Divya Chukkalore; Ahmed Elfiky; Mohammad Abureesh; Anum Aqsa; Chetan Singh; Chanudi Weerasinghe; Dhineshreddy Gurala; Seleshi Demissie; Liliane Deeb; Terenig Terjanian
Journal:  Gastroenterology Res       Date:  2022-07-12

4.  siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.

Authors:  Shane P Duggan; Catherine Garry; Fiona M Behan; Sinead Phipps; Hiromi Kudo; Murat Kirca; Abdul Zaheer; Sarah McGarrigle; John V Reynolds; Robert Goldin; Steve E Kalloger; David F Schaeffer; Aideen Long; Jessica Strid; Dermot Kelleher
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-01-31

5.  Mortality in gastro-oesophageal reflux disease in a population-based nationwide cohort study of Swedish twins.

Authors:  Eivind Ness-Jensen; Giola Santoni; Eivind Gottlieb-Vedi; Anna Lindam; Nancy Pedersen; Jesper Lagergren
Journal:  BMJ Open       Date:  2020-08-06       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.